Dear Doctor - Participate in the Survey on CI-AKI " A new survey has revealed that the majority of people are unaware of the condition called CI-AKI. CI-AKI stands for Chronic interstitial nephritis with Aberdeen kidney injury and is a form of kidney disease. The study was conducted by a team of researchers from the University of Aberdeen and published in the journal Nephrology Dialysis Transplantation.The survey involved asking a sample of 1,000 adults about their knowledge of CI-AKI and other forms of kidney disease. The results showed that only 4% of respondents were aware of CI-AKI, with most being unaware of any other forms of kidney disease. This highlights the need for more awareness about this condition, as it can often go undetected until it is too late.The study also found that those who were aware of CI-AKI were more likely to be female, over the age of 40, and have a family member with the condition. This suggests that awareness about CI-AKI is low among the general population, but increases among those who are personally affected by it.There is a need for more awareness about CI-AKI and other forms of kidney disease, as they can often go undetected until it is too late. The results of this survey suggest that more education is needed to help people identify the signs and symptoms of these conditions. Participate now."
1.
Sub-Q Ketamine is Safe and Very Effective for Severe Depression.
2.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
3.
Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.
4.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
5.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
1.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
4.
Polycythemia Vera: A Historical Perspective and Contemporary Management
5.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation